In cancer-immunity cycle, the immune checkpoint PD1 and its ligand PDL1 act as
accomplices to help tumors resist to immunity-induced apoptosis and promote tumor …

Cancer immunotherapy based on immune-checkpoint inhibition or adoptive cell therapy has
revolutionized cancer care. Nevertheless, a large proportion of patients do not benefit from …

Despite the success of anti-programmed cell death protein 1 (PD1), anti-PD1 ligand 1
(PDL1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies in advanced cancer, a …

Quantum biological tunnelling for electron transfer is involved in controlling essential
functions for life such as cellular respiration and homoeostasis. Understanding and …

T cells play a critical role in cancer control, but a range of potent immunosuppressive
mechanisms can be upregulated in the tumor microenvironment (TME) to abrogate their …

Tumor necrosis factor alpha (TNF)-dependent modulation of immune responses and cell
death processes has long been the subject of intense research. Yet, its role in cancer …

Cutaneous melanoma is the most common skin cancer with an incidence that has been
rapidly increasing in the past decades. Melanomas are among the most immunogenic …

Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced-
stage metastatic melanoma, as well as patients with many other solid cancers, yielding long …

Cancer immunotherapy utilizing blockade of the PD-1/PD-L1 checkpoint has revolutionized
the treatment of a wide variety of malignancies, leading to durable therapeutic responses not …

Antibodies against programmed cell death-1 (PD-1) have considerably changed the
treatment for melanoma. However, many patients do not display therapeutic response or …